UK government funding for dementia research has declined from its peak in 2018-2019. Despite this, the field shows high potential for research in the coming years. By 2040, over 1.2 million people in the UK are expected to have dementia, a 30% increase from 2022. The economic benefits of dementia research can be measured through an economic impact assessment (EIA), which considers various dimensions of dementia research. The report also highlights the significant impact of COVID-19 on people with dementia.
The risk of developing dementia or becoming an informal carer for a person with dementia is high. The study found that every £1 invested in dementia research generated £2.59 of economic benefit in the UK during 2019/20, and this is expected to increase to £2.91 on average in the next 20 years. Thus, increased investment in dementia research could improve the lives of those affected by dementia and create long-term economic growth in the UK.
🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?
Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.
#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs
🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?
The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.
Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.
#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess
🔍 Are you up-to-date with the latest advancements in HPV testing for head and neck cancer?
Our comprehensive article looks into the innovation of diagnostic methods for HPV status determination in head and neck squamous cell carcinoma (HNSCC). From traditional p16 immunohistochemistry to innovative liquid biopsies, discover the critical role these advancements play in prognosis, treatment planning, and improving patient outcomes.
Look into this essential topic and see how these insights could revolutionize clinical practices.
#SyenzaNews #oncology #HealthTech #HealthcareInnovation
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
